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A b s t r A c t
Digoxin is one of the oldest of cardiovascular drugs which is still frequently used, both 
in patients with atrial fibrillation (AF) and patients with heart failure with or without 
AF. The use of digoxin preceded the era of evidence based medicine. However, over 
the recent past, there has been growing evidence disputing and challenging the safety 
and efficacy of digoxin, while evidence has accumulated that a plethora of other thera-
pies for both heart failure and atrial tachyarrhythmias has proven more effective and 
safe. Nevertheless, digoxin still retains its role, albeit limited, in the current era, but 
most recent evidence has cast significant doubts about its safety. Thus, its role remains 
controversial and the drug should be reserved for specific patients and clinical scenar-
ios, with careful monitoring of its serum concentrations due to its narrow therapeutic 
and toxic ranges, maintaining it <0.8 ng/mL, with additional monitoring of serum 
electrolytes and renal function to avoid potential confounders that may enhance the 
proarrhythmic risk and susceptibility to digoxin toxicity.
I N t r O D U c t I O N
Digoxin has been included in our therapeutic armamentarium for heart failure 
and atrial tachyarrhythmias for over 200 years following Withering’s milestone work 
suggesting the therapeutic value of the plant foxglove in his 1785 classic monograph.1 
However, there has never been any evidence of a survival benefit,2 while recently, 
evidence has accumulated suggestive of a harmful effect.3-6 While in atrial fibrillation 
(AF) digoxin may have a role in the control of ventricular rate when added to beta-
blockers and calcium antagonists, which may have to be revisited in light of this recent 
evidence, digoxin for heart failure may no longer be a supportable option in view of 
all the data that have been accumulated todate. 
Since the results of the Digitalis Investigation Group (DIG) trial,2 indicating that 
digoxin does not reduce overall mortality, but it may reduce the rate of hospitalization 
both overall and for worsening heart failure, over long-term follow-up (3 years),2 but 
also during the first 30 days,7 the role of digoxin was further limited in the management 
of chronic heart failure, especially when more beneficial therapies for patients with 
heart failure were effected. Digoxin has also been employed in patients with AF to 
control the ventricular rate by enhancing vagal tone and thus decreasing conduction 
over the atrioventricular node. However, these effects are relevant only at rest and 
not during physical activity, since digoxin has limited utility in the setting of increased 
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sympathetic activity. Thus, for more effective rate control the 
drug should be used in combination with a beta-blocker or a 
calcium antagonist. Furthermore, digoxin’s beneficial effects 
are offset by its potential deleterious effects, arrhythmogenic 
potential, narrow therapeutic window and risk for serious 
drug interactions.
Indeed, recent meta-analyses and reviews of non-rand-
omized studies have suggested that digoxin use is associated 
with an increased risk of all-cause mortality in patients who 
have both heart failure and AF, even after adjustment for 
confounding variables. 
A t r I A L  F I b r I L L A t I O N
According with a US retrospective study (TREAT-AF: 
The Retrospective Evaluation and Assessment of Therapies in 
AF),6 among 122,465 male patients (mean age 72 years) with 
newly diagnosed nonvalvular AF with 353,168 person-years of 
follow-up, cumulative mortality rates were higher for 28,679 
(23.4%) digoxin-treated patients than for untreated patients 
(95 vs 67 per 1,000 person-years; p <0.001). Digoxin use was 
independently associated with mortality after multivariate 
adjustment (hazard ratio - HR: 1.26, p <0.001) and propensity 
matching (HR: 1.21, p <0.001), even after adjustment for drug 
adherence. The authors concluded that digoxin was associated 
with increased risk of death in patients with newly diagnosed 
AF, independent of drug adherence, kidney function, cardio-
vascular comorbidities, and concomitant therapies. 
Another US retrospective cohort study, the AnTicoagu-
lation and Risk factors In Atrial fibrillation-Cardiovascular 
Research Network (ATRIA-CVRN) study,8 comprising 
14,787 age- and gender-matched adults with incident AF and 
no previous heart failure or digoxin use, indicated that during 
a median 1.17 years of follow-up, digoxin use was associated 
with higher rates of death (8.3 vs 4.9 per 100 person-years; 
P <0.001) and hospitalization (60.1 vs 37.2 per 100 person-
years; P <0.001); digoxin use conferred a 71% higher risk of 
death (HR: 1.71) and a 63% higher risk of hospitalization (HR: 
1.63). The authors concluded that in adults with AF, digoxin 
use was independently associated with higher risks of death 
and hospitalization and thus it should be used with caution in 
the management of AF. 
A recent study investigated whether AF patients receiving 
rate control drugs (N=101,243) had a better prognosis com-
pared to those without rate-control treatment (N=168,678).9 
Rate controlled agents included beta-blockers (n=43,879), 
calcium channel blockers (n=18,466) and digoxin (n=38,898). 
During a follow-up of 4.9±3.7 years, mortality occurred in 
88,263 patients (32.7%). The risk of mortality was lower 
in patients receiving beta-blockers (HR: 0.76) and calcium 
channel blockers (HR: 0.93) compared to those who did not 
receive rate-control agents. On the contrary, the digoxin group 
had a higher risk of mortality with a HR of 1.12. The authors 
concluded that in this nationwide AF cohort, rate-control 
treatments with beta-blockers or calcium channel blockers 
reduced mortality, with beta-blockers conferring the largest 
risk reduction, while digoxin use was associated with greater 
mortality.
Even in a “real world” cohort of 815 AF patients on good 
anticoagulation treatment (time in therapeutic range - TTR 
~65%), the use of digoxin (n=171) was associated with an in-
creased risk of total mortality over a median follow-up of 33.2 
months.10 Indeed, multivariable analysis showed that digoxin 
was associated with total mortality (HR: 2.224, p <0.001) and 
cardiovascular death (HR: 4.686, p <0.001).
H E A r t  F A I L U r E
The Digitalis Investigation Group (DIG) trial was the 
pivotal trial showing that digoxin reduces the risk for hospi-
talization but not mortality among 6,800 stable patients (mean 
age 65 years) with heart failure (NYHA functional class II or 
III) and a left ventricular ejection fraction <45% who were 
in sinus rhythm.2 The DIG ancillary trial had a similar design 
and was conducted in parallel to the main study but included 
patients with ejection fractions >45% (“diastolic” heart fail-
ure or heart failure with preserved ejection fraction).11 The 
ancillary trial comprised 988 patients and found no effects 
on all-cause, cardiovascular, or heart failure mortality or on 
all-cause or cardiovascular hospitalizations. 
Post-hoc analyses of the DIG trial and other trial databases 
prompted the revised recommendation suggesting a much 
lower (0.5 to 0.8 ng/ml) than previously considered therapeutic 
serum digoxin level (1.0 to 2.0 ng/ml) in order to obtain the 
favorable effects of digoxin and avoid its deleterious conse-
quences on long-term survival.12 Unfortunately, despite these 
recommendations for lower dosing and the accumulation of 
worrisome data about the long-term use of digoxin, digoxin 
toxicity is not yet declining according with the US data, ac-
counting for an estimated 1% of emergency room visits for all 
adverse drug events among patients ≥40 years, rising to ~3% 
of emergency room visits and ~6% of hospitalizations for all 
adverse drug events among patients ≥85 years.13 
Recently, in the cohort of 1820 patients with mild heart 
failure (NYHA class I and II), prolonged QRS duration (>130 
ms), and reduced left ventricular ejection fraction (<30%) en-
rolled in the Multicenter Automatic Defibrillator Implantation 
Trial – Cardiac Resynchronization Therapy (MADIT-CRT) 
trial,14 digoxin therapy was not associated with an increased 
or decreased risk of heart failure/death (HR 1.07), heart 
failure alone (HR 1.1), or death alone (HR 0.93). However, 
digoxin was associated with a significant 41% increased risk of 
ventricular tachycardia/ventricular fibrillation (VT/VF) (HR 
1.41; P=0.002), which was driven by a significantly increased 
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risk of VT/VF with heart rate >200 bpm (HR 1.65; P <0.001), 
whereas no increased risk of VT/VF with heart rate <200 bpm 
was evident (HR 1.20; P=0.19). The authors concluded that 
the use of digoxin in patients with mild heart failure implanted 
with an implantable cardioverter defibrillator (ICD) or cardiac 
resynchronization therapy-defibrillator (CRT-D) device was 
not associated with reductions in heart failure/death events; 
however, digoxin therapy was associated with an increased 
risk of high-rate VT/VF.
A t r I A L  F I b r I L L A t I O N  
A N D  H E A r t  F A I L U r E
A meta-analysis of 10 studies (4 registries, 4 single-center 
cohort studies and 2 post-hoc analyses of randomized con-
trolled trials) comprising 76,100 patients with AF and heart 
failure indicated that over a follow-up period of 0.8-4.3 years, 
digoxin was associated with an increased risk of all-cause mor-
tality (relative risk - RR: 1.15, p=0.005).3 Subgroup analysis 
revealed that the pooled relative risk of all-cause mortality 
with the use of digoxin was similar between 8 observational 
studies (n=66,174, RR: 1.11) and 2 post-hoc analyses of 
randomized controlled trials (n=9926, RR: 1.27, interaction 
p=0.11). The authors concluded that digoxin use is associated 
with an increased risk of all-cause mortality in patients who 
have both heart failure and AF, even after adjustment for 
confounding variables. 
A meta-analysis of 11 observational studies, examin-
ing the relation between digoxin and all-cause mortality in 
318,191 patients with AF, indicated that over a mean of 2.8 
years, digoxin use was associated with a 21% increased risk 
for mortality (HR 1.21).15 Importantly, the use of digoxin was 
associated with an increase in mortality in patients with and 
those without heart failure. 
Use and outcomes of digoxin were examined in the 
Rivaroxaban Once Daily Oral Direct Factor xa Inhibition 
Compared with Vitamin K Antagonism for Prevention of 
Stroke and Embolism Trial in Atrial Fibrillation (ROCKET 
AF) trial.16 Among 14,171 AF patients (history of heart failure 
56%-73%; digoxin use at baseline 37%), digoxin was associ-
ated with increased all-cause mortality (5.41 vs 4.30 events 
per 100 patients-years; HR 1.17; p=0.0093), vascular death 
(3.55 vs 2.69 per 100 patient-years; HR 1.19; p=0.0201), and 
sudden death (1.68 vs 1.12 events per 100 patient-years; HR 
1.36; p=0.0076). The authors concluded that digoxin treatment 
was associated with a significant increase in all-cause mortality, 
vascular death, and sudden death in patients with AF, noting 
that this increased cardiovascular hazard was observed in those 
with and without heart failure. The authors also indicate that 
other drugs, such as β blockers and non-dihydropyridine cal-
cium channel antagonists, should be employed for rate control 
in patients with AF, whilst digoxin treatment should not be 
deemed a first-line treatment and should be used with caution 
in patients with AF with or without heart failure. They point 
out that further randomized studies are needed to define the 
optimum rate control therapies, including the role of digoxin.
Another meta-analysis of 19 reports (9 comprising AF 
patients, 7 heart failure patients, and 3 with both clinical 
conditions) indicated that among 326,426 patients, digoxin 
use was associated with an increased relative risk of all-cause 
mortality (HR 1.21, P <0.01).5 In the subgroup of reports 
comprising 235,047 AF patients, digoxin was associated with a 
29% increased mortality risk (HR 1.29) compared with subjects 
not receiving the drug. Among 91,379 heart failure patients, 
digoxin-associated mortality risk increased by 14% (HR 1.14). 
The authors concluded that digoxin use is associated with an 
increased mortality risk, particularly among patients suffering 
from AF.
The results of a more recent meta-analysis contrasted 
those of observational studies. This meta-analysis comprised 
52 studies and 621,845  patients, whereby digoxin users were 
2.4 years older than control, with lower ejection fraction (33% 
vs 42%), more diabetes, and greater use of diuretics and anti-
arrhythmic drugs.17 Compared with control, the pooled risk 
ratio for death with digoxin was 1.76 in unadjusted analyses, 
1.61 in adjusted analyses, 1.18 in propensity matched studies, 
and 0.99 in randomised controlled trials. Baseline differences 
between treatment groups appeared to have a significant im-
pact on mortality associated with digoxin, including markers 
of heart failure severity such as use of diuretics (P=0.004). 
Studies with better methods and lower probability of bias 
were more likely to report a neutral association of digoxin with 
mortality (P <0.001). Across all study types, digoxin led to a 
small but significant reduction in all cause hospital admission 
(risk ratio 0.92; P <0.001; n=29,525). The authors concluded 
that digoxin is associated with a neutral effect on mortality in 
randomised trials and a lower rate of admissions to hospital 
across all study types (there were 7 randomized trials included 
in the analysis conducted in 8,406 heart failure patients).
Furthermore, a recent analysis of data from the Outcomes 
Registry for Better Informed Treatment of Atrial Fibrilla-
tion (ORBIT-AF) study, among 9,619 patients with AF and 
serial follow-up every 6 months for up to 3 years, refuted the 
dismal results of prior reviews and meta-analyses, albeit only 
for patients with heart failure.18 In this cohort, 2,267 (23.6%) 
patients received digoxin at study enrollment, 681 (7.1%) were 
started on digoxin during follow-up, and 6,671 (69.4%) never 
received digoxin. Digoxin use at registry enrollment was not 
associated with subsequent onset of symptoms, hospitalization, 
or mortality (HR for death: 1.04 in heart failure patients; HR: 
1.22 in patients without heart failure). Incident digoxin use 
during follow-up was not associated with subsequent death in 
patients with heart failure (HR: 1.05), but was associated with 
subsequent death in those without heart failure (HR: 1.99). 
The authors concluded that digoxin use in registry patients 
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with AF had a neutral association with outcomes under most 
circumstances, but digoxin was associated with subsequent 
death in those without heart failure (HR: ~2.0).
Similarly, a recent survey of a prospective, multinational, 
observational registry of 1962 patients with AF, aged 56±16 
years, 36% having a digoxin prescription, and 27% having 
heart failure, indicated that digoxin therapy was associated 
with significantly higher mortality in those without heart 
failure at 6 months (8.7% vs 3.7%; odds ratio - OR: 5.07; P 
<0.001) and 12 months (12.3% vs 6.0%; OR: 4.22; P <0.001) 
but not in those with heart failure (6 months: 18.6% vs 14.7%; 
OR: 1.62; P=NS and 12 months: 25.4% vs 22.4%; OR: 1.37; 
P=NS).19 The authors concluded that in patients with AF and 
heart failure, digoxin did not offer any survival benefit, while 
in those without heart failure, digoxin therapy was associated 
with significantly higher long-term mortality.
c O N c L U s I O N  A N D  P E r s P E c t I v E
There appears to be convincing evidence accumulated to-
date suggesting that digoxin does not prolong survival in heart 
failure and/or AF patients, while there may be a significant 
risk of increased cardiovascular mortality in these patients. 
The data from recent reviews and meta-analyses, admittedly 
mostly from observational studies, are worrisome and should 
be taken into serious consideration, especially in the current 
era, when we have much better and safer alternative therapies 
for both heart failure and atrial fibrillation. It may not possible 
to have in the future a randomized controlled trial that may 
be able to shed further light into this matter, while the results 
from other meta-analyses refuting, albeit not entirely, the 
dismal outcome of digoxin usage suggested by the majority of 
  Digoxin Use*
 HF patients AF patients  AF/HF patients
 not responding  (no real need)
 to standard Rx  combine with β-blocker (HFrEF)
   combine with β-blocker/CCB (HFpEF)
 to ↓ hospitalization rate  to ↓ ventricular rate
  Dose: ≤0.125 mg qd/qod
  Serum digoxin level 0.5-0.8 ng/mL 
  (T ½ = 36 h when renal function is normal / steady state at 5 half-lives)
  Monitor electrolyte & renal status
  Drug Interactions
  (e.g. amiodarone, dronedarone, propafenone, quinidine, verapamil, tetracycline, erythromycin)
*Avoid or extreme caution (much lower doses) in the elderly (≥75-80 years) & patients with renal insufficiency (GFR ≤45-60 ml/
min)/Digoxin toxicity: correct hyperkalemia, hypokalemia, and hypomagnesemia; correction of electrolyte imbalances may reverse 
dysrhythmias/Digoxin immune Fab is extremely effective in the treatment of moderate to severe digoxin toxicity
FIgUrE 1. A suggested algorithm for selective use of digoxin, if at all. With regards to digoxin toxicity, physicians should be alert and 
vigilant to discern between digoxin effect/ no toxicity (i.e., scooped ST-segment or ST-sagging), early toxicity (e.g. atrial or ventricu-
lar ectopy, bradyarrhythmia), moderate toxicity (i.e., ventricular arrhythmias, junctional rhythm), or severe life-threatening toxicity 
(i.e., complete or high-degree AV block, ventricular tachyarrhythmias and hyperkalemia).12 AF = atrial fibrillation; CCB = calcium 
channel blocker(s); GFR = glomerular filtration rate; HF = heart failure; HFpEF = heart failure with preserved ejection fraction; 
HFrEF = heart failure with reduced ejection fraction; qd = once daily; qod = every other day; Rx = treatment. 
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prior reviews and meta-analyses of observational data, do not 
appear to provide any convincing answers that would alleviate 
one’s fears for the potential perilous effects of digoxin. 
Thus, it is possible that we are indeed approaching the 
end of the digoxin era, saving it for now for only specific 
circumstances, such as patients with heart failure who are not 
responding well to standard therapies in hope of reducing their 
hospitalization rate, and patients with both heart failure and 
AF who cannot tolerate or do not respond to other available 
rate controlling agents. Even in such clinical conditions of last 
resort, one has to consider using the lowest possible dose of 
digoxin while maintaining its serum levels <0.8 ng/mL,20 with 
additional monitoring of serum electrolytes and renal function 
to avoid potential confounders that may enhance the proar-
rhythmic risk and susceptibility to digoxin toxicity (Fig. 1). 
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